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  Implication for health policy/practice/research/medical 
education:
Hepatitis B is a common viral disease that highly appears among 
high risk groups. Therefore, study of this article is recommended to 
the epidemiologists, hepatologists, virologists and other research-
ers who are interested in the ﬁeld of public health.
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As a practicing physician, I face clinical problems every 
day. To solve them, I use clinical decision making skills 
including reaching the most accurate diagnosis and de-
ciding on the next step or steps to manage the problem. 
A clinician is a pragmatic person; i.e., s/he needs practi-
cal, implementable data to guide reasoning or decision 
making and nothing else! In this environment, why is 
Mohammad Reza Ghadir’s article on the epidemiology 
of Hepatitis B virus infection in this issue of the journal 
at all?  (1). Of course it is a Socratic question, and you may 
ﬁnd me to be the author of similar articles (2).  Descrip-
tion and research on epidemiology from the aspects of 
incidence and prevalence will aﬀect pre-test likelihood 
in clinical decision-making. When a doctor encounters 
a patient in daily practice, s/he needs to know the pos-
sibility of the presence of a condition or disease when a 
sign or symptom is present; therefore the background 
epidemiology of the disease in the population that the 
patient comes from is important. It is especially impor-
tant when there are limited data regarding the popula-
tion; for example when there is a demographic shift due 
to immigration to a new area or a change of transmis-
sion-related factors after universal HBV vaccination. In 
terms of infectious disease, these epidemiologic shifts 
may be rapid and may necessitate surveillance and trend 
analysis through point estimation studies. In the con-
text Ghadir reported, there is a dynamic, ever-migrating 
population and a disease whose epidemiology changes 
frequently. Epidemiologic studies may help indicate pos-
sible risk factors, especially when using methodologies 
that include attributable risk calculations. The risk fac-
tors may be manageable in a clinical setting or may be 
used by health authorities to plan preventive projects for 
the community. This approach may be combined with an 
estimation of risk factor manipulation in the patient as 
a single case as well as in the community. For example, 
if there is an established attributable risk of intravenous 
drug use with needle sharing that could disseminate 
the infection in the community, you may put an HBV 
patient on Methadone maintenance therapy (MMT). On 
the other hand, in a case of monogamous sexual contact 
with an HBcAb-positive sex partner at the age of 50, you 
may conclude that there is no need to recommend bar-
rier methods. Along these lines, the risk factor tables in 
the Ghadir articles attempt to guide us. This is a method-
ological change and results in a nested case-control type 
of plan within a large cross-sectional study. When the 
prevalence of a disease is low and consequently the cases 
within a sample of population are limited, analyzing 
risk factors will result in methodological problems. This 
is the problem that Ghadir encounters in some rows of 
his table, for example when analyzing tattooing as a risk 72
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factor. On other hand, when there is a shared risk factor 
in the majority of the sample and there is no measure-
ment of higher or lower exposure rates, the researcher 
cannot conclude that this factor is essentially a risk or 
not. Consider unsafe barber practices within a male 
population and its eﬀect on HBV transmission. The last 
evidence-gathering step before concluding on clinical 
guidelines would be a decision analysis study. The formal 
methodology in such studies is to draw a decision tree 
and conduct reverse calculations. To enable the calcula-
tion, probabilities are needed for each arm, and to deﬁne 
the probabilities, it is essential to know the prevalence 
and incidence of each subgroup, which are extractable 
from epidemiologic studies. Even when a researcher in-
tends to do a sensitivity analysis as part of the decision 
analysis, the ideal conclusion will be reached when the 
epidemiologic variations are known and a systematic 
review performed, such as that done by Alavian et al. in 
their publication on HBV epidemiology (3). In terms of 
data consistency, a new piece of information on the same 
HBV epidemiology surely does not add anything to our 
current preventive and clinical practice; in such circum-
stances when associated with limited manpower and 
ﬁnancial support, resources are better shifted toward 
other studies. Along with the importance of population-
based epidemiologic studies, I would like to note that, in 
terms of scientiﬁc reasoning, dissociating such studies 
from other biomedical studies on infectious transmis-
sion and risk factors may result in a reductionist phi-
losophy.  Without knowing the etiopathogenesis of the 
disease, variations in humans from the viewpoint of ge-
nomics, proteomics, and even metabolomics will result 
in pitfalls that have happened throughout the history of 
medicine.
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